GlaxoSmithKline plc (GSK)
| Market Cap | 93.36B |
| Revenue (ttm) | 46.71B |
| Net Income (ttm) | 7.88B |
| Shares Out | 2.52B |
| EPS (ttm) | 3.15 |
| PE Ratio | 12.00 |
| Forward PE | 13.77 |
| Dividend | $0.80 |
| Dividend Yield | 2.12% |
| Trading Day | April 16 |
| Last Price | $37.75 |
| Previous Close | $37.69 |
| Change ($) | 0.06 |
| Change (%) | 0.16% |
| Day's Open | 37.82 |
| Day's Range | 37.62 - 37.90 |
| Day's Volume | 7,972,537 |
| 52-Week Range | 32.26 - 41.01 |
It looks like GlaxoSmithKline PLC (NYSE:GSK) has poked the bear.
It looks like GlaxoSmithKline PLC (NYSE:GSK) has poked the bear.
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
"I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.
An activist investor is reportedly building a significant position in the drugmaker.
GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the ...
GlaxoSmithKline gained Thursday on a report activist investor Elliott Management has built a "significant" stake in the pharmaceutical giant. In early action, GSK stock gapped up.
GlaxoSmithKline PLC (LON:GSK) is on the radar of hedge fund group Elliott Management Advisers, according to a report today. The activist fund manager has acquired what was described as a significant sta...
Activist hedge fund Elliott Management has taken a multi-billion pound stake in British pharmaceutical firm GlaxoSmithKline, the Financial Times reported on Thursday.
The small biotech is getting critical help from a big pharma company.
One of the three clearly has the most upside potential.
Cheap, solid stocks may seem like a mirage considering the equity bull run, but several excellent investments are trading at a discount. The post 7 Cheap Stocks That Won't Be on Discount for Long appear...
There are five billion reasons these companies hope it's not.
Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, R...
GlaxoSmithKline PLC (LON:GSK) announced it will help produce up to 60mln doses of the Coronavirus (COVID-19) vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm s...
GlaxoSmithKline PLC (LON:GSK) announced it will help making up to 60mln doses of the COVID-19 vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm signed an agreem...
GlaxoSmithKline Plc (NYSE: GSK) has agreed to handle the final part of the manufacturing process for up to 60 million doses of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine for use in the U.K. GSK will ...
These 7 high-yield dividend stocks have yields above 5% and their payout ratios broadly look strong enough to support those dividends. The post 7 High-Yield Dividend Stocks With Enough Earnings to Cover...
The following three stocks have underperformed the broader market recently. They are also in considerable financial distress, as represented by poor Altman Z-Scores, meaning they are in danger of going ...
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investi...
GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
GlaxoSmithKline fired Dr. Moncef Slaoui from the board for Galvani Bioelectronics on Wednesday on allegations he sexually harassed a GSK employee. In response, GlaxoSmithKline stock dipped.
GlaxoSmithKline PLC (LON:GSK) announced it has fired Moncef Slaoui as chair of Galvani Bioelectronics, a chronic disease research firm where it is the majority shareholder. Slaoui is the former head of ...
Moncef Slaoui, former chief scientist of Operation Warp Speed during the Trump administration, was fired as Galvani Bioelectronics' board chairman over “substantiated” sexual harassment allegations by a...
Glaxosmithkline said that Moncef Slaoui has been dismissed as chairman of Galvani Bioelectronics, which is majority owned by GSK.
According to the High Dividend Yield Stocks page, a Premium feature of GuruFocus, five stocks with a dividend yield of at least 4% and double-digit guru buys over the past few months are AbbVie Inc. (NY...
Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.
Privately-held Boston Pharmaceuticals has announced a three-year out-license and option agreement with GlaxoSmithKline Plc (NYSE: GSK) to advance pre-phase 2 programs. Initially, GSK will out-license an...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will b...
Vectura Group PLC (LON:VEC) said it will pay a special dividend of £115mln during 2021 after receiving millions from GlaxoSmithKline PLC (LON:GSK) regarding a US patent litigation. The FTSE 250 pharma c...
GlaxoSmithKline PLC (LON:GSK) has started Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate developed by Canadian partner Medicago. Takashi Nagao, Medicago's chief executive, said: ...
GlaxoSmithKline Plc (NYSE: GSK) hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA (NASDAQ: SNY). GSK and Medicago will start Pha...
QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
GlaxoSmithKline (GSK) closed at $35.55 in the latest trading session, marking a -0.14% move from the prior day.
GlaxoSmithKline and Vir Biotechnology said Wednesday their antibody drug reduced the risk of hospitalization and death in high-risk Covid-19 patients — and Vir stock catapulted Thursday. The post Vir St...
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod
An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profoun...
GlaxoSmithKline PLC (LON:GSK) said an independent data monitoring committee (IDMC) recommended to stop the final phase of trials on a COVID-19 treatment because it's very effective. VIR-7831 is a monocl...
The relationship could result in a marriage down the line.
The biotech's pipeline gets a seal of approval.
It's a real possibility.
Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's Covid-19 treatment, leading Vir stock to plummet Wednesday. Shares fell more than 27%.
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
GlaxoSmithKline PLC (LON:GSK) said it is tweaking clinical studies on a COVID-19 treatment candidate after missing the primary goal. Otilimab, a monoclonal antibody, did not make a significant differenc...
Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest vaccine c...
About GSK
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, ... [Read more...]
| Industry Drug Manufacturers-General | Founded 1715 |
| CEO Emma Walmsley | Employees 94,066 |
| Stock Exchange NYSE | Ticker Symbol GSK |
Financial Performance
In 2020, GSK's revenue was 34.10 billion, an increase of 1.02% compared to the previous year's 33.75 billion. Earnings were 5.75 billion, an increase of 23.77%.
Analyst Forecasts
According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 46.57, which is an increase of 23.36% from the latest price.